• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·688085.SS
Share

Shanghai Sanyou Medical Co., Ltd Stocks

CN¥ 12.72Last Updated 13.10.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 726.81M

CN¥ 12.72
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Headquartered in Shanghai, China, Shanghai Sanyou Medical Co., Ltd. focuses on the entire lifecycle of orthopedic implants, from their initial research and development through manufacturing and ultimately sales within the Chinese market. The company distributes its medical devices under the Tytus and Sanyou brand names, primarily specializing in spinal and trauma-related implants. Its spinal product line features a broad selection, including anterior cervical plates, anterior and posterior thoracolumbar systems, posterior cervical solutions, and z-minimally invasive products. For trauma injuries, Sanyou Medical offers implant systems designed for various anatomical regions, such as the shoulder and elbow, hip and pelvis, knee, and palm and wrist.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.10.2026 14:26

From ASML to Micron: The Chipmaker Sell-off Spread Across Europe and Asia and Returned to the U.S.

13.10.2026 13:42

The Russell 2000 has fallen nearly 9% from its peak and is nearing a correction. What should investors do?

13.10.2026 13:27

An analyst expects a sharp increase in Google's AI spending. He named three stocks that stand to benefit

13.10.2026 12:57

Shares of luxury companies plummeted: LVMH reported a decline in sales in its core business segment

13.10.2026 12:26

BlackRock Downgraded Its Outlook on U.S. Stocks but Remained Bullish on AI. What Has Changed in the Past Month?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026